



EHA2023 abstracts: What's hot in MDS?

To help navigate the exciting content being presented at the EHA2023 Congress, the MDS Hub Steering Committee have provided their recommendations for the top abstracts to look out for in MDS.



Click
the abstracts
to view

This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at <https://mds-hub.com/>. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.

Oral abstract sessions and poster presentations

Friday, June 9

Abstract	Type	Title	Presenter
S165	Oral presentation	<u>Continuous transfusion independence with imetelstat in heavily transfused non-del(5q) lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis stimulating agents in IMERGE phase 3</u>	Uwe Platzbecker
S169	Oral presentation	<u>Modulation of the immune landscape in lower-risk myelodysplastic syndromes with imetelstat-induced transfusion independency</u>	Nicolas Chapuis
P492	Poster presentation	<u>Safety and efficacy of LP-108 as monotherapy and combined with azacitidine in patients with relapsed/refractory myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia</u>	Kristin Koenig
P689	Poster presentation	<u>Classification of MDS and AML based solely on genetics omitting blast counting – a way to resolve the discrepancies between classifications according to WHO and ICC?</u>	Claudia Haferlach
P724	Poster presentation	<u>Updated substudy results for ivosidenib in <i>IDH1</i>-mutant relapsed/refractory myelodysplastic syndrome</u>	Courtney DiNardo
P732	Poster presentation	<u>Analysis of patient-reported fatigue in IMERGE Ph3 trial of imetelstat vs placebo in heavily transfused non-del(5q) lower-risk myelodysplastic syndromes R/R to erythropoiesis stimulating agents</u>	Mikkael Sekeres
P733	Poster presentation	<u>Treatment patterns and outcomes among patients with lower-risk myelodysplastic syndromes receiving luspatercept in routine clinical practice in the United States</u>	Sudipto Mukherjee
P736	Poster presentation	<u>Analysis of response rates and outcomes in erythroid-predominant myelodysplastic syndromes (MDS) treated with venetoclax-based regimens</u>	Alexandre Bazinet
P1270	Poster presentation	<u>Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: results of a randomized clinical trial comparing 2 fractionation schedules</u>	Uday R. Popat
P1290	Poster presentation	<u>Upfront allogeneic hematopoietic stem cell transplantation can provide survival benefit versus hypomethylating agent in myelodysplastic syndrome with increased blasts I (MDS-IBI)</u>	Runzhi Ma

Oral abstract sessions and poster presentations

Saturday, June 10

Abstract	Type	Title	Presenter
S102	Plenary session	<u>Luspatercept versus epoetin alfa for treatment (tx) of anemia in ESA-naive lower-risk myelodysplastic syndromes (LR-MDS) patients (pts) requiring RBC transfusions: data from the phase 3 commands study</u>	Matteo Giovanni Della Porta
S164	Oral presentation	<u>Disease modifying activity of imetelstat in patients with heavily transfused non-del(5q) lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis stimulating agents in IMERGE phase 3</u>	Valeria Santini
S172	Oral presentation	<u>Phase 1/2 study of oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia</u>	Alex Bataller
S173	Oral presentation	<u>Retrospective study of lenalidomide discontinuation in patients with myelodysplastic syndrome harboring del(5q). A harmony alliance study</u>	Elena Crisà
S174	Oral presentation	<u>Myeloid NGS analyses of paired samples from bone marrow and peripheral blood yield concordant results: a prospective cohort analysis of the AGMT study group</u>	Lisa Pleyer
s265	SWG session	<u>Myelodysplastic syndromes: myelodysplastic neoplasms given the new WHO classification</u>	Chair: Uwe Platzbecker



Follow us on Twitter to keep up to date
with the latest from the EHA2023 Congress!

@MDS_Hub
#EHA2023
<https://mds-hub.com/>